The company reported positive late-stage trial results for its drug Camzyos in adolescent patients, expanding its cardiovascular portfolio. An analyst raised the price target to $60 from $54, citing significant pipeline optionality with 12 key data readouts expected in 2026. The company is positioned as a cheap S&P 500 stock, and its balance sheet is viewed as healthy. Management is confident its pipeline can help navigate upcoming patent expiries for major drugs later this decade.